Comparison · NCT03976102-deaths
Arm A: DRL_RI vs Arm B: MabThera®: deaths from any cause
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Arm A: DRL_RI vs Arm B: MabThera®: deaths from any cause. Trial comparisons, record NCT03976102-deaths. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT03976102-deaths
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.0185 | 0.00632 | 0.053 | wilson | |
| Risk in group 2 | 0.0131 | 0.00359 | 0.0464 | wilson | |
| Risk difference, group 1 minus group 2 | 0.00545 | -0.03 | 0.0412 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 1.42 | 0.24 | 8.36 | log | |
| Odds ratio, group 1 over group 2 | 1.42 | 0.235 | 8.64 | log | |
| Number needed to harm, for one more death from any cause on Arm A: DRL_RI than on Arm B: MabThera® | 184 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Arm A: DRL_RI | Randomized participants were administered DRL\_RI 375mg/m\^2 via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36. | 3 | 162 | EG000 |
| Group 2 | Arm B: MabThera® | Randomized participants were administered MabThera® 375 mg/m\^2 via IV infusion on Days 1, 8, 15, 22 and Weeks 12, 20, 28 and 36. | 2 | 153 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, all-cause mortality
- Time frame
- From Screening (Day -28 to -1) up to 52 weeks
Source ClinicalTrials.gov
Trial
- Title
- Compare Efficacy, Safety, and Immunogenicity of Proposed Rituximab Biosimilar (DRL_RI) With MabThera® in LTB Follicular Lymphoma
- NCT number
- NCT03976102
- Phases
- PHASE3
- Conditions
- Follicular Lymphoma
- Interventions
- DRL_RI (Proposed rituximab biosimilar), MabThera®
- Lead sponsor
- Dr. Reddy's Laboratories Limited
- Results first posted
- 2024-01-22
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT03976102?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT03976102-deaths